MSLN and neoplasm: The ADC anetumab ravtansine, a fully human anti-mesothelin antibody (MF-T) coupled via a reducible disulfide linker to a microtubule-targeting toxophore DM4, binds to mesothelin with high affinity and delivers the microtubule inhibitor DM4 to mesothelin-positive tumor cells [31].